Variable Features of Juvenile Polyposis Syndrome With Gastric Involvement Among Patients With a Large Genomic Deletion of BMPR1A

Autor: Yael Goldberg, Elizabet Half, Ephrat Levy-Lahad, Lina Basel-Salmon, Lior H. Katz, Zohar Levy, Mahmud Mansur, Shlomi Cohen, Menachem Schechter, Ariela Tomer, Eliahu Golomb, Tamar Peretz, Tom Walsh, Rachel Beeri, Rachel Berger, Sari Lieberman, Harold Jacob, Mary Claire King, Suleyman Gulsuner, Dan Keret, Inbal Kedar
Rok vydání: 2019
Předmět:
Male
Esophageal Neoplasms
Colorectal cancer
Gastroenterology
Loss of heterozygosity
0302 clinical medicine
Medicine
Juvenile polyposis syndrome
Israel
Sequence Deletion
Aged
80 and over

Genome
biology
Intestinal Polyposis
Intestinal Polyps
Middle Aged
Pedigree
3. Good health
Phenotype
Child
Preschool

Gastritis
030220 oncology & carcinogenesis
Female
030211 gastroenterology & hepatology
Colorectal Neoplasms
Adult
Heterozygote
medicine.medical_specialty
Adolescent
Tumor suppressor gene
Colon
Article
Young Adult
03 medical and health sciences
Testicular Neoplasms
Neoplastic Syndromes
Hereditary

Internal medicine
Humans
PTEN
Alleles
Bone Morphogenetic Protein Receptors
Type I

Aged
business.industry
Juvenile Polyp
Point mutation
medicine.disease
digestive system diseases
BMPR1A
Jews
biology.protein
business
Zdroj: Clinical and Translational Gastroenterology
ISSN: 2155-384X
DOI: 10.14309/ctg.0000000000000054
Popis: Juvenile polyposis syndrome (JPS, OMIM 174900) is a rare autosomal dominant disorder, affecting between 1 in 100,000 and 1 in 160,000 (1), characterized by hamartomatous polyps and increased risk of gastrointestinal (GI) cancer. JPS is diagnosed clinically when a person has any one of the following: (i) more than 5 juvenile polyps of the colon or rectum; (ii) juvenile polyps in other parts of the GI tract; or (iii) any number of juvenile polyps and one or more affected family members (National Comprehensive Cancer Network [NCCN] guidelines) (2). Up to 60% of individuals with clinically defined JPS are now found to exhibit mutations in SMAD4 or BMPR1A genes (3). JPS polyps are typically colonic with edematous, markedly inflamed lamina propria, with cystic dilation and smooth muscle proliferation. Although dysplastic polyps may appear with variable histology, one study reported “mixed polyposis syndrome” with polyps containing variable pathology of adenomatous, hyperplastic, and juvenile features caused by small base pair deletions in the BMPR1A gene (4); adenomas comprise less than 10% of JPS polyps (5). JPS can involve the entire GI tract. Although colonic phenotype is similar between patients with SMAD4 and BMPR1A mutations, upper GI and gastric polyposis is much more common in SMAD4 mutation (1,6,7). As reported by Aretz et al. (6), SMAD4 mutation carriers had a significantly higher frequency of gastric polyposis than did patients with BMPR1A mutations (83% vs 8%, respectively). All cases of gastric cancer occurred in families with SMAD4 mutations (6,7). Lifetime risk estimates of GI cancers, mostly colorectal cancer (CRC), are highly variable, ranging from 14% to 55% in different series (1,8,9). Although surveillance guidelines exist, the NCCN guidelines for surveillance recommend referral of patients with JPS to a specialized team due to the rarity of the syndrome and complexities of diagnosis and management (2). The molecular alterations involved in polyp and tumor formation in JPS are attributed to defective BMP signaling, where aberrant BMP signaling disrupts stem cell self-renewal and differentiation, contributing to tumor formation (10). Loss of heterozygosity (LOH) was reported in half of BMPR1A-related polyps, compatible with BMPR1A acting as a tumor suppressor gene (11). However, BMPR1A LOH has not been documented yet in cancerous tumors. Most pathogenic variants in BMPR1A are point mutations or small deletions. Large deletions of BMPR1A are rare, accounting for approximately 6% of cases, many of them are contiguous with PTEN (6,12–14). Contiguous gene deletions may lead to more pronounced manifestations; however, the rarity and variability of BMPR1A deletions not including PTEN have made genotype-phenotype relationships of large BMPR1A deletions difficult to assess (14). We identified a deletion of the entire coding region of the BMPR1A gene among and investigated the clinical features in over 50 individuals from 7 unrelated families. This cohort enables expanding our knowledge about this rare predisposition syndrome.
Databáze: OpenAIRE